| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
92,610,000 |
| Market
Cap: |
2.13(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.07 - $31.94 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. Co. has three clinical-stage ex vivo lentiviral vector. These include programs for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,355,932 |
| Total Buy Value |
$0 |
$0 |
$0 |
$19,999,997 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
418,173 |
438,811 |
467,219 |
487,632 |
| Total Sell Value |
$11,574,225 |
$12,042,227 |
$12,602,151 |
$12,990,263 |
| Total People Sold |
7 |
7 |
7 |
8 |
| Total Sell Transactions |
12 |
14 |
24 |
29 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Yalamanchi Naveen |
Director |
– • • |
2021-08-27 |
4 |
A |
$32.48 |
$26,390,520 |
I/I |
812,516 |
16,272,635 |
|
- |
|
| Makker Gotham |
|
• • – |
2021-07-27 |
4 |
GD |
$0.00 |
$0 |
I/I |
621,500 |
674,901 |
|
- |
|
| Makker Gotham |
|
• • – |
2021-06-17 |
4 |
S |
$47.13 |
$18,850 |
I/I |
(400) |
1,296,401 |
|
33% |
|
| Makker Gotham |
|
• • – |
2021-06-16 |
4 |
S |
$46.85 |
$1,624,843 |
I/I |
(34,685) |
1,296,801 |
|
37% |
|
| Yalamanchi Naveen |
Director |
– • – |
2021-05-11 |
4 |
S |
$40.03 |
$29,023,490 |
I/I |
(725,000) |
15,460,119 |
|
23% |
|
| Shah Gaurav |
CEO |
• • – |
2021-04-01 |
4 |
D |
$45.21 |
$1,032,554 |
D/D |
(22,266) |
495,639 |
|
- |
|
| Shah Gaurav |
CEO |
• • – |
2021-03-31 |
4 |
D |
$45.94 |
$344,235 |
D/D |
(7,493) |
517,905 |
|
- |
|
| Shah Gaurav |
CEO |
• • – |
2021-03-31 |
4 |
D |
$44.24 |
$3,887,647 |
D/D |
(87,353) |
525,398 |
|
- |
|
| Shah Gaurav |
CEO |
• • – |
2021-03-31 |
4 |
OE |
$1.69 |
$128,237 |
D/D |
75,880 |
612,751 |
|
- |
|
| Shah Gaurav |
CEO |
• • – |
2021-03-30 |
4 |
D |
$41.80 |
$3,720,492 |
D/D |
(85,888) |
536,871 |
|
- |
|
| Yalamanchi Naveen |
Director |
– • – |
2021-03-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,344,925) |
16,185,119 |
|
- |
|
| Patel Kinnari |
Chief Operating Officer |
• • – |
2021-03-24 |
4 |
OE |
$1.21 |
$131,979 |
D/D |
93,962 |
188,939 |
|
- |
|
| Schwartz Jonathan David |
Chief Medical Officer |
• • – |
2021-02-01 |
4 |
OE |
$1.21 |
$277,166 |
D/D |
224,529 |
224,529 |
|
- |
|
| Patel Kinnari |
Chief Operating Officer |
• • – |
2020-12-28 |
4 |
AS |
$56.51 |
$950,745 |
D/D |
(16,761) |
94,977 |
|
-22% |
|
| Yalamanchi Naveen |
Director |
– • – |
2020-12-10 |
4 |
B |
$56.00 |
$13,872,320 |
I/I |
247,720 |
17,530,044 |
2.1 |
-25% |
|
| Shah Gaurav |
President & CEO |
• • – |
2020-03-24 |
4 |
D |
$13.78 |
$449,848 |
D/D |
(32,645) |
1,028,997 |
|
- |
|
| Shah Gaurav |
President & CEO |
• • – |
2020-03-24 |
4 |
OE |
$0.43 |
$39,098 |
D/D |
90,925 |
1,061,642 |
|
- |
|
| Patel Kinnari |
Chief Operating Officer |
• • – |
2020-03-18 |
4 |
B |
$9.50 |
$9,500 |
I/I |
1,000 |
6,675 |
0.01 |
152% |
|
| Shah Gaurav |
President & CEO |
• • – |
2020-02-25 |
4 |
D |
$20.15 |
$125,595 |
D/D |
(6,233) |
970,717 |
|
- |
|
| Shah Gaurav |
President & CEO |
• • – |
2020-02-25 |
4 |
OE |
$0.43 |
$125,628 |
D/D |
290,000 |
976,950 |
|
- |
|
| Yalamanchi Naveen |
Director |
– • – |
2019-12-10 |
4 |
B |
$22.25 |
$5,006,250 |
I/I |
225,000 |
17,282,324 |
2.1 |
- |
|
| Yalamanchi Naveen |
|
• • • |
2019-04-16 |
4 |
B |
$17.50 |
$9,625,088 |
I/I |
550,005 |
17,057,324 |
0.01 |
- |
|
| Shah Gaurav |
See Remarks |
• • – |
2019-03-05 |
4 |
AS |
$16.90 |
$422,500 |
D/D |
(25,000) |
686,950 |
|
- |
|
| Shah Gaurav |
See Remarks |
• • – |
2019-03-04 |
4 |
AS |
$17.28 |
$430,272 |
D/D |
(24,900) |
711,950 |
|
- |
|
| Shah Gaurav |
See Remarks |
• • – |
2019-03-01 |
4 |
AS |
$17.34 |
$433,500 |
D/D |
(25,000) |
736,850 |
|
- |
|
135 Records found
|
|
Page 4 of 6 |
|
|
0.38 (1.63%) 
